StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals CVS Caremark by Year

CVS Caremark — Share of gross accounts receivable (historical, %) (%)

Vertex Pharmaceuticals CVS Caremark: 1,700.0% in FY2016, unchanged from a year earlier. No newer figure appears in the documents we track.

Latest, FY2016
1,700.0%
Period ended Dec 31, 2016
Change on a year earlier
0.0 pts
1,700.0% in FY2015
History
2 years
Since FY2015
Sources
2
Documents cited below

Where the FY2016 figure comes from

Source: Form 10-K (filed 2018-02-15) ↗

Reported in Form 10-K Note (Significant Revenue & Receivable Concentrations).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCVS Caremark — Share of gross accounts receivable (historical, %) (%)Year on yearSource
FY2016Dec 31, 20161,700.0%0.0 ptsForm 10-K (filed 2018-02-15) ↗
FY2015Dec 31, 20151,700.0%–Form 10-K (filed 2017-02-23) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals CVS Caremark (%), annual FY2015–FY2016 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/conc-cvs-ar

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.